share_log

Aphex BioCleanse Systems Inc Announces It Has Filed A Debtor In Possession Plan In The Florida Middle District Bankruptcy Court

Aphex BioCleanse Systems Inc Announces It Has Filed A Debtor In Possession Plan In The Florida Middle District Bankruptcy Court

Aphex BioCleanse Systems Inc宣佈,它已向佛羅裏達州中區破產法院提交了一份債務人佔有計劃
GlobeNewswire ·  2022/08/15 21:50

Venice, FL, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Aphex BioCleanse Systems, Inc. (OTCPK: SNST), which had filed a voluntary petition under the Federal Bankruptcy Code, Chapter 11, Subchapter V with the Petition being filed on May 12, 2022 in the United States Bankruptcy Court Middle District of Florida Tampa Division states today that as of August 12, 2022 they timely filed a Debtor In Possession Plan (DIP) with the Court.

環球通訊社,佛羅裏達州威尼斯,2022年8月15日-Aphex BioCleanse Systems,Inc.(OTCPK:SNST)已根據聯邦破產法第11章第五小節提交了自願請願書,並於2022年5月12日向美國破產法院提交了請願書,佛羅裏達州坦帕市中區分部今天表示,截至2022年8月12日,他們及時向法院提交了債務人佔有計劃(DIP)。

David R Olund, President states, "the filing of a DIP Plan is a very important step in the reorganization and recovery of Aphex BioCleanse Systems Inc. The Company is actively seeking out DIP investment capital which along with an approved DIP Plan could set the Company on a solid course towards operational stability and profitability."

總裁表示:“提交DIP計劃是Aphex BioCleanse Systems Inc.重組和恢復過程中非常重要的一步。該公司正在積極尋找DIP投資資本,再加上批准的DIP計劃,將使公司走上穩定運營和盈利的堅實道路。”

The Bankruptcy filing was precipitated by the litigatory actions of former Corporate Directors in concert with certain other shareholders, which is viewed by current management as an attempted hostile takeover and to be without merit as well as damaging to shareholder interests.

破產申請是由前公司董事與某些其他股東一致採取的訴訟行動促成的,目前的管理層認為這是一種企圖的敵意收購,沒有可取之處,而且損害了股東的利益。

The Company management is working diligently to relaunch its marketing with new germ-killing products and to engage the necessary DIP financing.  

公司管理層正在努力用新的殺菌產品重新開始營銷,並進行必要的DIP融資。

"We thank the majority of our shareholders who we serve and who support our amazing technologies. We look forward to their consensus with the DIP Plan which will ultimately be voted on by the Company Creditors and Shareholders.", says David Olund – President.

大衞·奧倫德-總裁説:“我們感謝我們服務的大多數股東,感謝他們支持我們令人驚歎的技術。我們期待着他們就DIP計劃達成共識,該計劃最終將由公司債權人和股東投票表決。”

About Aphex BioCleanse Systems, Inc. (Aphex):

關於Aphex BioCleanse Systems公司(Aphex):

Aphex is the developer of the world's first proprietary non-alcohol, non-toxic, hydrogen-based cleaning technology, and has been producing germ killing solutions for over 10 years. The technology, called Hy-IQ® Water, has a unique method of sanitizing that you won't find anywhere else.  Hy-IQ® Water uses hydrogen ions traveling nearly at the speed of light to breach the cell walls of exoskeleton germs.

Aphex是世界上第一個專有的無酒精、無毒、基於氫氣的清潔技術的開發商,10多年來一直在生產殺菌解決方案。這項名為Hy-IQ的技術®水,有一種獨特的消毒方法,你在其他地方找不到的。HY-IQ®水利用氫離子以接近光速的速度穿透外骨骼細菌的細胞壁。

"We Kill Germs with Physics, Not Chemistry" is a tagline that expresses their commitment to the environment by providing non-Chemical solutions to the spread of dangerous pathogens.  Killing the most dangerous germs on the planet, while meeting the EPA's definition of "Water", is revolutionary.

“我們用物理而不是化學殺死細菌”是一句標語,通過為危險病原體的傳播提供非化學解決方案來表達他們對環境的承諾。消滅地球上最危險的細菌,同時滿足環境保護局對“水”的定義,是一種革命性的做法。

To find out more about Aphex and their technologies, visit Aphex BioCleanse Systems, Inc. - Superior Sanitization (aphexus.com)

欲瞭解更多有關Aphex及其技術的信息,請訪問Aphex BioCleanse Systems,Inc.-Superior Sanitiization(apexus.com)。

Forward-Looking Statements:

前瞻性陳述:

This current press release contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future, including but not limited to, any products sold or cash flow from operations. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with distribution and difficulties associated with obtaining financing on acceptable terms. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all the information set forth herein and should also refer to our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time to time with the Securities and Exchange Commission.

本新聞稿包含“前瞻性陳述”,這一術語在1933年的美國證券法第27A節和1934年的證券交易法第21E節中有定義。本新聞稿中非純粹歷史性的陳述為前瞻性陳述,包括有關對未來的信念、計劃、預期或意圖的任何陳述,包括但不限於已售出的任何產品或來自運營的現金流。由於許多因素,實際結果可能與任何前瞻性陳述中預測的結果不同。這些因素除其他外,包括與分銷有關的內在不確定性,以及與以可接受的條件獲得融資有關的困難。這些前瞻性陳述是截至本新聞稿發佈之日作出的,我們沒有義務更新前瞻性陳述,也沒有義務更新實際結果可能與前瞻性陳述中預測的結果不同的原因。儘管我們相信本新聞稿中包含的信念、計劃、預期和意圖是合理的,但不能保證這些信念、計劃、預期或意圖將被證明是準確的。投資者應參考本文中列出的所有信息,也應參考我們上一財年的最新年度報告、我們的季度報告以及不時提交給美國證券交易委員會的其他定期報告。

Investor Contact:

投資者聯繫方式:

Anthony Marrotti
585-880-1567
amorotti@aphexus.com

安東尼·馬羅蒂
585-880-1567
郵箱:amorotti@apexus.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論